Welcome Ivan. SNTA's biggest problems were that management was initially too focused on Ganetespib as a monotherapy. AS you state, Ganetespib has an excellent safety profile, and that makes it very amenable to combination therapies, which thankfully management has now fully embraced. A second issue is that management was setting itself up for disappointments by making comments about impressive efficacy signals well before trials were completed, or even significantly through the trial. It looks like they have finally learned their lesson, to keep expectations low and their heads down until the data starts rolling so the data can speak for itself. Lastly, management is moving forward in breast cancer where an HSP90i should be very efficacious as ERBs are major clients of HSP90.
SNTA definitely needs more cash. I would be surprised if they don't issue some shares before Galaxy-1 final results are released. They need to do this as insurance. Obviously they won't if they generate a partnership deal before the final Galaxy-1 results are in, but they do need to raise cash one way or another. If people can't see this they shouldn't be invested in SNTA or any other biotech for that matter.
""Second, I want to see that one day Quarthon declare himself: "hey guys, you are right, I am truely a moron".""
First, everybody KNOWS he or she is a moron, so what difference would it make to read him or her acknowledge the obvious.
Second, he or she is such an exceedingly big moron that doesn't have the cognitive ability to recognize that he or she is indeed a moron, or more precisely, the king of morons.
""Wednesday is The Day! The Dragonfly - Doji is NEVER wrong! Mark my words!""
I will say that it is wrong.
stewart, why would you use margin to such an extent that it forces you to sell before you are ready? Seems like a risky move to me!
texasblackswan, you are half right. Quorthon is a waste. However, jfk provided obvious and often wrong or over-hyped information. Yes someone who knew nothing about SNTA might get intrigued enough to take a closer look, but long term longs are simply annoyed by jfk and his constant pumping and touting chartist non-sense as if it were a sure thing predictor. That is laughable for a small cap biotech with only developmental products.
Kwackers, his credibility was never questionable to me. It was very obvious to me that the guy was a spammer from the beginning.
syenfrout, These chartists trying to tell us how a small biotech will do make me laugh even more than I do when chartists try and tell us ho any other stock will do. There are the only things you can bank on. If the final Galaxy-1 data for the 6 months patient group is good where the Ganetespib + Docetaxel arm and shows a statistically significant improvement in OS, SNTA will rise. If the Enchant-1 Ganetespib + paclitaxel arm shows excellent efficacy, or even the Ganetespib alone arms hold up after the full 33 patient cohort is treated, SNTA will rise.
Janet, I took your advice and sold more to book more losses to offset my ONXX gains. I have left about 1/10 of my peak shares of PGNX. The ones I still have were ones I bought at under $4 so I will hold these. Plenty of time to buy some PGNX back later as we are unlikely to get any major news that could positively impact the stock until early next year. The nice part for me is that the sale of ONXX went though earlier this week so close to 70% of my stock account is now in cash. I am just watching the market decline calmly and just biding my time to get back in to some bargains. The old adage that it is better to be lucky than good comes to mind. Good luck to you!
It will be nice when jfk & quorthon go away. Even thought I have them both on ignore, they still pollute the board with serial non-sense.
jabberwocky75, Really?? You sold but didn't tell anyone until afterwards. That sure sounds suspicious, in other words, sure you did.
H, ha. A pharmacist and biotech investment consultant writing about a company he is invested in deeply. Ha, ha. Chris is an uber long and his "analysis" isn't worth the paper it is written on. Since it isn't actually written on paper, you can see how little that is worth. I especially liked the part where he wrote about a partnership being a certainly that will be worth a kings ransom. Ha, ha. Bavi has never been shown to significantly improve survival in a controlled trial, the most advanced trial, the phase II NSCLC trial was corrupted and contains 50% censored patients in the 3mg/kg arm,
Janet, I sold off 1/3 of my shares a little more than a week ago at $5.26 and put in an order to sell another 1/3 at $5.13 this morning. I needed to lock in some losses as the ONXX deal was finalized so my pgnx losses will reduce my gains somewhat. I will buy some back after the wash sales time has been reached. I am pleased that an advisory committee will meet, but it sucks that it will take so long. March 2014 will be close to 2 years since the FDA ruling on Relistor in chronic pain was issued. Good luck.
Too bad we didn't get a deal that was cash + AMGN shares rather than all cash. Still, I can't complain about the ONXX buyout.
The post deserves a thumbs down because it is non-sense posted by a delusional pumper. PPHM fares poorly compared to the NASDAQ in almost any time frame you can use. The fact that a pumper finds one very short time frame where the opposite is true is meaningless and irrelevant.
I love it when someone like alan calls others imbeciles, then displays their own ignorance. You don't even know how to properly use" their ". Here is some more news for you. The tea party imbeciles are responsible as they submit a budget they know will be rejected. As far as Obamacare, the Republicans refused to be involved in any aspect of crafting the law, or in trying to improve it after it was passed, signed into law then upheld as constitutional by the Supreme Court. The fact that you call Obamacare dung demonstrates you lack of knowledge of that law, and your familiarity with dung.
Joybug, glad to see you recognize that getting fast track is about FDA review process timing, and about unmet medical needs. I am long SNTA. Obviously understanding biology is important for helping to make informed decisions, and as a research scientist I do. It is also important to get basic info correct, and this JFK person has been a font of misinformation. Examples are his or her thinking Galaxy1 is a monotherapy, a failure to understand why SNTA will be moving forward with Ganetespib as a combo in breast cancer, to the touting of essentially all rehashed data as some spectacular new data in Galaxy 1. I have high hopes for my SNTA investment, but I don't like pumpers like JFK crowding the boards with repetitive hype and errors.
jonesdexter, Don't be so stupid. The looming government shutdown and the prospects the imbecile tea party will push the country to default over the debt ceiling is what the problems are now.
lexkyvol, ha, ha, you are a phony guy. I will stack my accurate and sober posts about SNTA against those by the superficial pumper JFK anytime. I feel sorry for you if you think that guy is a font of wisdom. Here is one of mine you from Sept 25th that you should read.
"Respitamycin had liver and ocular toxicity issues because of its hydrophobicity. INFI converted it to a salt, respitamycin:HCl in the hopes the ionic form would not have toxicity issues. the problem is that 50% of the salt converts in the blood, due to blood pH) back to the free base. They had to lower the dosage to make sure it wouldn't reach toxic levels and there was no guarantee the salt would be as efficacious.
The idea that if one HSPi inhibitor fails means all will fail is absurd. there are many tyrosine kinase inhibitors on the market and they have different efficacies in different cancer types. An excellent example is the comparison of Sutent and Nexavar. The failure of Respitamycin is INFI specific, and as such I think this is a buying opportunity regarding SNTA"